irsogladine has been researched along with Adverse Drug Event in 1 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
| Excerpt | Relevance | Reference |
|---|---|---|
| " The incidence and maximum severity of fluorouracil-induced oral mucositis and safety of the irsogladine dosing regimen were evaluated." | 2.78 | Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. ( Hayashi, K; Kamata, M; Kojima, H; Nomura, M; Sawada, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Sawada, S | 1 |
1 trial available for irsogladine and Adverse Drug Event
| Article | Year |
|---|---|
Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Drug-Related Side | 2013 |